英文公司新闻Company News

Phase II Clinical Trial of Tasly Biopharma PUK (Recombinant Human Pro-urokinase for Injection) Thrombolysis for the Treatment of Acute Pulmonary Embolism Successfully Completes the Enrollment

Recently, the last subject was…

继续阅读 Phase II Clinical Trial of Tasly Biopharma PUK (Recombinant Human Pro-urokinase for Injection) Thrombolysis for the Treatment of Acute Pulmonary Embolism Successfully Completes the Enrollment